Etelcalcetide Treatment for Left Ventricular Hypertrophy in Hemodialysis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Patients with chronic kidney disease on hemodialysis develop left ventricular hypertrophy, which contributes to cardiac issues like congestive heart failure and increased risk of sudden cardiac death, with elevated fibroblast growth factor 23 (FGF23) levels playing a significant role, but the effectiveness of etelcalcetide in reducing or retarding this progression is not well understood.
Innovation Solution
Administering etelcalcetide parenterally, intravenously, or subcutaneously to subjects on chronic hemodialysis or peritoneal dialysis for at least 12 months to alleviate, slow, or delay the progression of left ventricular hypertrophy, as measured by left ventricular mass index through cardiac magnetic resonance imaging, thereby reducing circulating FGF23 levels and mitigating cardiac fibrosis.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If etelcalcetide is administered to patients on hemodialysis, then left ventricular hypertrophy progression is reduced, but the mechanism and effectiveness were previously unknown
Solution Approach 1:
The patent implements a feedback mechanism by measuring FGF23 levels before and after etelcalcetide administration, and correlating these measurements with changes in left ventricular mass index. This feedback loop establishes the causal relationship between FGF23 reduction and LVH progression slowing, transforming the previously unknown mechanism into a measurable and predictable treatment effect.
2Duration of action of stationary object
If etelcalcetide administration is extended to 12 months or longer, then progression of left ventricular hypertrophy is slowed, but the treatment duration and commitment increase
Solution Approach 1:
The patent establishes baseline FGF23 levels and left ventricular mass index measurements before initiating etelcalcetide treatment. This preliminary action creates a reference point that allows for early assessment of treatment effectiveness, enabling clinicians and patients to evaluate whether the time commitment is yielding the expected benefits before the full 12-month duration is completed.
3Device complexity
If left ventricular hypertrophy is left untreated, then the treatment complexity is minimized, but cardiac death risk and heart failure progression increase
Solution Approach 1:
The patent identifies FGF23 as an intermediary substance that mediates the relationship between etelcalcetide administration and left ventricular hypertrophy progression. By targeting this specific intermediary (FGF23) rather than attempting to directly reduce left ventricular mass, the treatment achieves therapeutic effect through a specific biological pathway, providing a rational basis for the treatment complexity while effectively reducing cardiac death risk.
Data Source
AI summary
Disclosed are methods for treatment of a subject with left ventricle hypertrophy. Also disclosed are methods for slowing or delaying progression of left ventricle hypertrophy, as well as methods for mediating cardiac remodeling and for improving cardiac function in subjects with left ventricle hypertrophy. The methods comprise administering etelcalcetide parenterally to a subject.